Skip to main content

Schizophrenia & Psychotic Disorders

October 15, 2019
The US Food and Drug Administration (FDA) has approved a transdermal patch formulation of asenapine (Secuado) as the first patch for the treatment of adults with schizophrenia, Noven Pharmaceuticals, Inc. announced.
October 04, 2019
SAN DIEGO—Just half of survey respondents who took oral antipsychotics for schizophrenia thought the medication did more good than harm, according to research presented during poster sessions at Psych Congress 2019.
September 16, 2019
Genetic variants associated with left-handedness influence brain connectivity and might be related to the pathogenesis of such neuropsychiatric diseases as Parkinson's disease and schizophrenia, researchers from UK report.
September 13, 2019
Use of a transdermal patch to administer the second-generation anti-psychotic blonanserin improves both positive and negative symptoms of acute schizophrenia with manageable adverse effects, a new industry study shows.
September 06, 2019
Increased striatal activation in response to unexpected positive feedback may represent a neurological brain marker for psychosis risk, suggests a study published online in Neuropsychopharmacology. Psychosis is strongly associated with heightened levels of dopamine in the striatum, a brain region…
September 04, 2019
Taking psychiatric medication did not hamper weight loss in people who participated in a structured weight loss program, researchers recently reported online in the journal Obesity. The study compared weight loss outcomes for 17,519 adults enrolled in a lifestyle weight management program at the…
August 29, 2019
Long-acting injectable (LAI) antipsychotics are superior to oral antipsychotics for preventing rehospitalization in older adults with schizophrenia, researchers report in The American Journal of Geriatric Psychiatry.
August 22, 2019
Extending olanzapine treatment beyond remission of psychotic-depression symptoms may lower relapse rates, according to findings from the STOP-PD II randomized clinical trial.
August 21, 2019
The use of second-generation antipsychotics (SGAs) is associated with an increased risk of cataracts in people with schizophrenia, researchers report.
Back to Top